Cerebral Aspergillosis: Diagnostic Challenges, Therapeutic Strategies, and Future Research

Louise Chantelot1, Emilie Sitterlé2, Sylvain Poirée3

  • 1Infectious Diseases and Tropical Medicine Department, Necker-Enfants Malades Hospital, Assistance Publique-Hôpitaux de Paris, Université de Paris, Paris, France.

CNS Drugs
|November 10, 2025
PubMed

Insights

Cerebral aspergillosis, a severe fungal infection in immunocompromised patients, presents diagnostic challenges and limited treatments. This review covers its epidemiology, diagnostics, and antifungal drug therapies for the central nervous system.

Area of Science:

  • * Neurology
  • * Infectious Diseases
  • * Mycology

Background:

  • * Cerebral aspergillosis is a severe manifestation of invasive aspergillosis.
  • * Primarily affects immunocompromised individuals, leading to high morbidity and mortality.
  • * Diagnostic challenges and limited treatment options contribute to poor outcomes.

Purpose of the Study:

  • * To review the epidemiology and risk factors of cerebral aspergillosis.
  • * To examine diagnostic issues and current drug treatment strategies.
  • * To discuss antifungal pharmacokinetics/pharmacodynamics in the CNS and emerging resistance.

Main Methods:

  • * Comprehensive literature review of cerebral aspergillosis.
  • * Analysis of epidemiological data and risk factors.
  • * Evaluation of diagnostic modalities and antifungal therapies.

Main Results:

  • * Cerebral aspergillosis epidemiology and risk factors are detailed.
  • * Diagnostic challenges and their impact are highlighted.
  • * Antifungal drug properties and resistance patterns in CNS infections are examined.

Conclusions:

  • * Cerebral aspergillosis requires improved diagnostic and therapeutic approaches.
  • * Understanding antifungal CNS penetration and resistance is crucial.
  • * Further research is needed to address treatment gaps and improve patient outcomes.